Reducing Antibacterial Development Risk for GSK1322322 by Exploring Potential Human Dose Regimens in Nonclinical Efficacy Studies Using Immunocompetent Rats

Directly testing proposed clinical dosing regimens in nonclinical studies can reduce the risk during the development of novel antibacterial agents. Optimal dosing regimens can be identified in animal models by testing recreated human pharmacokinetic profiles. An example of this approach using contin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Antimicrob Agents Chemother
Hlavní autoři: Hoover, Jennifer L., Singley, Christine M., Elefante, Philippa, DeMarsh, Peter, Zalacain, Magdalena, Rittenhouse, Stephen
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Microbiology 2017
Témata:
Experimental Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5655044/
https://ncbi.nlm.nih.gov/pubmed/28807913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00959-17
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky